Authors
Latest:
Ipilimumab Combined With Nivolumab for the Treatment of Patients With MelanomaAnna C. Pavlick, MD, associate professor, co-director, Melanoma Program, assistant director, Clinical Research Education, discusses a study that examined two immunotherapy agents, ipilimumab and nivolumab, in patients with melanoma.
Latest:
Challenges in Treating Small Cell Lung CancerAnna Farago, MD, PhD, assistant, medicine, Massachusetts General Hospital, discusses challenges in treating small cell lung cancer.
Latest:
A Study of Brentuximab Vedotin Plus AVD in Hodgkin LymphomaAnna Sureda, MD, PhD, Head of the Clinical Hematology Service at the Institut Català d'Oncologia – Hospitalet de Llobregat in Barcelona, discusses the phase III ECHELON-1 study exploring brentuximab vedotin plus doxorubicin, vinblastine, dacarbazine (A+AVD) versus ABVD in patients with previously untreated stage III or IV Hodgkin lymphoma.
Latest:
Managing PD-L1-Positive NSCLC in the Long-TermAnne Chiang, MD, PhD, discusses the takeaways from her presentation given at the 18th Annual New York Lung Cancers Symposium.
Latest:
Dr. Anne Covey on Locoregional Therapy in Hepatocellular CarcinomaAnne Covey, MD, discusses options for patients with hepatocellular carcinoma (HCC) who cannot undergo resection or transplant.
Latest:
Breast Density in Black Versus White WomenAnne Marie McCarthy, PhD, research fellow, Massachusetts General Hospital, discusses a study that examined breast density, a risk that can help target breast cancer, in black women compared to white women.
Latest:
Future Targeted Therapy Approaches in NSCLCAnne S. Tsao, MD, and Edward B. Garon, MD, MS, conclude their discussion with a look to the future of TROP2 and associated targeted therapy approaches in non–small cell lung cancer.
Latest:
Presence of MSI-H, MMR-D Predicts Lynch Syndrome Across Tumor TypesResults from a prospective study involving 15,045 tumor samples that underwent next-generation sequencing using MSK-IMPACT and microsatellite-instability testing demonstrate that MSI-high and DNA mismatch-repair deficient tumors are predictive of Lynch syndrome across all tumor types. The results suggest that LS-associated cancers may be more heterogeneous than previously suspected.
Latest:
Dr. Elias Discusses the Future of Androgen Receptors in Breast CancerAnthony D. Elias, MD, professor, Division of Medical Oncology, University of Colorado Denver, discusses the future of androgen receptors in breast cancer.
Latest:
Sequencing Therapy in the Current Treatment Landscape of CholangiocarcinomaAnthony El-Khoueiry, MD, provides a brief review of sequencing therapy for patients with cholangiocarcinoma in the modern treatment landscape.
Latest:
Patient With a PIK3CA-Positive Tumors Exhibits Hyperglycemia Associated With AlpelisibThe approval of alpelisib in May 2019 poses a challenge to oncologists and their practices with the emergence of hyperglycemia as an AE associated with PI3K inhibitors. Managing the patient effectively requires a multidisciplinary team approach that involves counseling up front, monitoring throughout the course of therapy, and input and feedback from the team of oncologists, advanced practice providers, pharmacists, and dietitians.
Latest:
The Role of the Pathologist During Melanoma TreatmentAnthony M. Magliocco, MD, discusses the pathologist’s role when treating a patient with melanoma.
Latest:
Limited Following of Best Practices for CLL Observed in the Real-World SettingAnthony Mato, MD, MSCE, discusses an observational registry study of real-world prognostic biomarker testing, treatment patterns and treatment dosing in a pool of 1461 patients with either chronic lymphocytic leukemia.
Latest:
Immune Checkpoint Blockade: A New Strategy for the Treatment of Breast CancerBreast cancer has traditionally not been viewed as immunogenic. There is now a growing body of evidence that immune infiltration has a prognostic role in al breast cancer subtypes, and predicts improved clinical outcome in triple-negative and human epidermal growth factor receptor 2-positive tumors.
Latest:
Sequencing Agents for the Treatment of Patients With MelanomaAntoni Ribas, MD, PhD, professor of Hematology and Oncology and director of the Tumor Immunology Program Area at UCLA Jonsson Comprehensive Cancer Center, discusses how to appropriately sequence therapies for patients with melanoma.
Latest:
Niraparib Maintenance Improves PFS in Frontline Ovarian CancerAntonio Gonzalez Martín, MD, discusses the results from the phase III PRIMA study, which evaluated the PARP inhibitor niraparib versus placebo as a frontline treatment of patients with newly diagnosed ovarian cancer who responded to platinum-based chemotherapy.
Latest:
The Role of the ID2 Protein in Brain CancerAntonio Iavarone, MD, professor of Pathology and Cell Biology and Neurology, Columbia University, Institute for Cancer Genetics, discusses the role of the ID2 protein in patients with malignant brain tumors.
Latest:
One Expert's Vision for Breast Cancer Treatment in the Next 5 to 10 YearsAntonio Llombart-Cussac, MD, PhD, medical oncologist, chairman, Medical Oncology Service, University Hospital Arnau de Vilanova in Valencia, Spain, discusses his vision for breast cancer treatment in the next 5 to 10 years.
Latest:
Overcoming Resistance to Agents Treating BRAF Mutations in Colorectal CancerPrecision and personalized medicine targeting driver mutations has revolutionized cancer care in the past decade. Targeted therapy has entered the world of colorectal cancer research with the identification of mutations in KRAS and BRAF genes.
Latest:
The Impact of Darolutamide on Dose Modification of mHSPCArash Rezazadeh Kalebasty, MD, discusses the dose modification impact of the addition of darolutamide for patients with metastatic hormone sensitive prostate cancer.
Latest:
New Combination Builds Upon Existing Therapies for Anaplastic AstrocytomaArati Desai, MD, explains how the results from the phase III STELLAR trial will enhance knowledge of anaplastic astrocytoma.
Latest:
Emerging Therapies for the Treatment of Mantle Cell LymphomaAri M. Melnick, MD, from Weill Cornell Medical College, comments on emerging therapies for the treatment of mantle cell lymphoma.
Latest:
The Challenges of Measuring Tumor HeterogeneityAri Melnick, MD, a professor of medicine at the Weill Cornell Medical College, discusses the challenges associated with measuring tumor heterogeneity.
Latest:
Immunoscore Provides Risk Assessments for All Stages of Colon CancerIn a presentation at the 33<sup>rd</sup> Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cance, Dr. Galon discussed the definition of the immune contexture of Immunoscore, its international validation for the risk-classification of stage I-III colon cancer, and the potential value of Immunoscore in stage IV metastatic disease.
